SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hyo Jin Kim, Ju-Yeon Cho, Yu Jin Kim, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee, Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients, The Korean Journal of Internal Medicine, 2015, 30, 1, 32

    CrossRef

  2. 2
    J. L. Hou, Z. L. Gao, Q. Xie, J. M. Zhang, J. F. Sheng, J. Cheng, C. W. Chen, Q. Mao, W. Zhao, H. Ren, D. M. Tan, J. Q. Niu, S. J. Chen, C. Pan, H. Tang, H. Wang, Y. M. Mao, J. D. Jia, Q. Ning, M. Xu, S. M. Wu, J. Li, X. X. Zhang, Y. Ji, J. Dong, J. Li, Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial, Journal of Viral Hepatitis, 2015, 22, 2
  3. 3
    Seong Hee Kang, Hyung Joon Yim, Hae Rim Kim, Keunhee Kang, Sang Jun Suh, Hyun Jung Lee, Eileen L. Yoon, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun, Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B, Journal of Clinical Gastroenterology, 2014, 1

    CrossRef

  4. 4
    Cho I Lee, So Young Kwon, Jeong Han Kim, Won Hyeok Choe, Chang Hong Lee, Eileen L. Yoon, Jong Eun Yeon, Kwan Soo Byun, Yun Soo Kim, Ju Hyun Kim, Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure, Gut and Liver, 2014, 8, 1, 64

    CrossRef

  5. 5
    Jeong Heo, Sang Hoon Ahn, Young-Oh Kweon, Byung-Ho Kim, Henry L Y Chan, Andrzej Horban, Suchat Wongcharatrawee, Cyril Llamoso, Kwan Sik Lee, Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2014, 29, 7
  6. 6
    J. K. Dyson, J. Waller, A. Turley, E. Michael, S. Moses, M. Valappil, M. Hudson, M. Bassendine, S. McPherson, Hepatitis B in pregnancy, Frontline Gastroenterology, 2014, 5, 2, 111

    CrossRef

  7. 7
    Andreas Geipel, Dieter Glebe, Hans Will, Wolfram H. Gerlich, Hepatitis B Virus rtI233V Mutation and Resistance to Adefovir, New England Journal of Medicine, 2014, 370, 17, 1667

    CrossRef

  8. 8
    EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee, Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir, Clinical and Molecular Hepatology, 2014, 20, 3, 267

    CrossRef

  9. 9
    Hyun Young Woo, Jong Young Choi, Seung Kew Yoon, Dong Jin Suh, Seung Woon Paik, Kwang Hyub Han, Soon Ho Um, Byung Ik Kim, Heon Ju Lee, Mong Cho, Chun Kyon Lee, Dong Joon Kim, Jae Seok Hwang, Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus, Clinical and Molecular Hepatology, 2014, 20, 2, 168

    CrossRef

  10. 10
    Guan Huei Lee, Myat Oo Aung, Yock Young Dan, Yin Mei Lee, Belinda Mak, How Cheng Low, Kieron Lim, Maung Aye Thwin, Poh Seng Tan, Seng Gee Lim, Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?, Journal of Medical Virology, 2013, 85, 1
  11. 11
    Xiao-Lin Deng, Qing-Ling Li, Jin-Jun Guo, Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy, Virus Genes, 2013, 47, 1, 1

    CrossRef

  12. 12
    Jia-Jie Lu, Kai Liu, Yuan-Ji Ma, Juan Wang, En-Qiang Chen, Hong Tang, Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil, Journal of Viral Hepatitis, 2013, 20,
  13. 13
    Ambreen Ayub, Usman Ali Ashfaq, Asma Haque, HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level, BioMed Research International, 2013, 2013, 1

    CrossRef

  14. 14
    E. S. Svarovskaia, M. Curtis, Y. Zhu, K. Borroto-Esoda, M. D. Miller, T. Berg, F. Lavocat, F. Zoulim, K. M. Kitrinos, Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen, Journal of Viral Hepatitis, 2013, 20, 2
  15. 15
    Hyung Joon Yim, Seong Gyu Hwang, Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade, Clinical and Molecular Hepatology, 2013, 19, 3, 195

    CrossRef

  16. 16
    Chao-ying Hu, Yan-mei Liu, Yun Liu, Qian Chen, Wei Wang, Kai Wu, Jie Dong, Jie Li, Jing-ying Jia, Chuan Lu, Shi-xuan Sun, Chen Yu, Xuening Li, Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects, Clinical Therapeutics, 2013, 35, 12, 1884

    CrossRef

  17. 17
    Fabien Lavocat, Paul Dény, Christian Pichoud, Nasser Al Hawajri, Kathryn Kitrinos, Katyna Borroto-Esoda, Fabien Zoulim, Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy, Journal of Hepatology, 2013, 59, 4, 684

    CrossRef

  18. 18
    Wai-Kay Seto, Man-Fung Yuen, James Fung, Ching-Lung Lai, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection, Hepatology International, 2013, 7, 2, 327

    CrossRef

  19. You have free access to this content19
    Geoffrey Dusheiko, Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues, Liver International, 2013, 33,
  20. 20
    Bruno Roche, Didier Samuel, Treatment of Patients with HBV-related Decompensated Cirrhosis and Liver Transplanted Patients, Clinics in Liver Disease, 2013, 17, 3, 451

    CrossRef

  21. 21
    Bo Liu, Xin Wen, Canhua Huang, Yuquan Wei, Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years, The International Journal of Biochemistry & Cell Biology, 2013, 45, 9, 1987

    CrossRef

  22. 22
    Ningqiang Tian, Zhengwen Liu, Mingbo Yang, Zhu Li, Guoyu Zhang, Qunying Han, Na Li, Qianqian Zhu, Yi Lv, Yawen Wang, Fanfan Xing, Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension, Virology Journal, 2012, 9, 1, 273

    CrossRef

  23. 23
    Xia Zhou, XueMei Kuang, Ke Fan, ChangJiang Zhang, GuoHong Deng, HuiFen Wang, YuMing Wang, Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance, Journal of Medical Virology, 2012, 84, 7
  24. 24
    KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109

    CrossRef

  25. 25
    Olivier Lada, Anne Gervais, Michel Branger, Gilles Peytavin, Benedicte Roquebert, Gilles Collin, Gil Fraqueiro, Rami Moucari, Gwen Hamet, Michelle Martinot-Peignoux, Sophie Matheron, Patrick Marcellin, Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G, Liver International, 2012, 32, 1
  26. 26
    C. Q. Pan, K.-Q. Hu, A. S. Yu, W. Chen, C. Bunchorntavakul, K. R. Reddy, Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir, Journal of Viral Hepatitis, 2012, 19, 3
  27. 27
    Sara Baraldi, Nilay Hepgul, Valeria Mondelli, Carmine M. Pariante, Symptomatic Treatment of Interferon-α–Induced Depression in Hepatitis C, Journal of Clinical Psychopharmacology, 2012, 32, 4, 531

    CrossRef

  28. 28
    Arianeb Mehrabi, Majid Esmaeilzadeh, Hamidreza Fonouni, Mohammadreza Hafezi, Nuh N. Rahbari, Mohammad Golriz, Ali Majlesara, Morva Tahmasbi Rad, Mahmoud Sadeghi, Jan Schmidt, Tom M. Ganten, The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation, Langenbeck's Archives of Surgery, 2012, 397, 5, 697

    CrossRef

  29. 29
    Yu Jin Kim, Seung Woon Paik, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  30. 30
    Mauro Viganò, Pietro Lampertico, Antiviral drugs for HBV liver disease, Expert Opinion on Biological Therapy, 2011, 11, 3, 285

    CrossRef

  31. 31
    Mashu Aizawa, Akihito Tsubota, Kiyotaka Fujise, Keiko Tatsuzawa, Midori Kono, Sadayori Hoshina, Hisao Tajiri, Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients, Journal of Medical Virology, 2011, 83, 6
  32. 32
    Helen Dakin, Morris Sherman, Scott Fung, Carrie Fidler, Anthony Bentley, Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective, PharmacoEconomics, 2011, 29, 12, 1075

    CrossRef

  33. 33
    Pietro Lampertico, Mauro Viganò, Massimo Colombo, Current Management of HBV Antiviral Drug Resistance, Current Hepatitis Reports, 2011, 10, 2, 120

    CrossRef

  34. 34
    Corinne Buchanan, Tram T. Tran, Current Status of Liver Transplantation for Hepatitis B Virus, Clinics in Liver Disease, 2011, 15, 4, 753

    CrossRef

  35. 35
    J. Inoue, Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, Y. Yamagiwa, M. Shiina, Y. Kondo, E. Kakazu, K. Tamai, N. Obara, T. Iwasaki, T. Shimosegawa, Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern, Journal of Viral Hepatitis, 2011, 18, 3
  36. 36
    Akshay Kapoor, Vidyut Bhatia, Sarath Gopalan, Anupam Sibal, Hepatitis B in children—current status, Apollo Medicine, 2011, 8, 4, 287

    CrossRef

  37. 37
    P. Lampertico, M. Vigano, F. Facchetti, F. Invernizzi, A. Aroldi, G. Lunghi, P. G. Messa, M. Colombo, Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B, Nephrology Dialysis Transplantation, 2011, 26, 6, 2037

    CrossRef

  38. 38
    J. W. Park, H. S. Kim, D. D. Seo, J. S. Jang, W. G. Shin, K. H. Kim, M. K. Jang, J. H. Lee, H. Y. Kim, D. J. Kim, M. S. Lee, C. K. Park, Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance, Journal of Viral Hepatitis, 2011, 18, 10
  39. You have free access to this content39
    W. S. Ayoub, E. B. Keeffe, Review article: current antiviral therapy of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2011, 34, 10
  40. 40
    Derek Yu, Jenny Heathcote, Tenofovir in the treatment of chronic hepatitis B, Therapy, 2011, 8, 5, 527

    CrossRef

  41. 41
    E. Jenny Heathcote, Patrick Marcellin, Maria Buti, Edward Gane, Robert A. De Man, Zahary Krastev, George Germanidis, Samuel S. Lee, Robert Flisiak, Kelly Kaita, Michael Manns, Iskren Kotzev, Konstantin Tchernev, Peter Buggisch, Frank Weilert, Oya Ovunc Kurdas, Mitchell L. Shiffman, Huy Trinh, Selim Gurel, Andrea Snow–Lampart, Katyna Borroto–Esoda, Elsa Mondou, Jane Anderson, Jeff Sorbel, Franck Rousseau, Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B, Gastroenterology, 2011, 140, 1, 132

    CrossRef

  42. You have free access to this content42
    George V. Papatheodoridis, Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues, Liver International, 2011, 31,
  43. 43
    Markus Peck-Radosavljevic, Johann Deutsch, Peter Ferenci, Ivo Graziadei, Harald Hofer, Heidemarie Holzmann, Wolf-Dietrich Huber, Herman Laferl, Andreas Maieron, Rudolf Stauber, Wolfgang Vogel, 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009, Wiener klinische Wochenschrift, 2010, 122, 9-10, 280

    CrossRef

  44. 44
    Vandana Khungar, Steven-Huy Han, A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2010, 9, 2, 75

    CrossRef

  45. 45
    A. Tamori, M. Enomoto, S. Kobayashi, S. Iwai, H. Morikawa, H. Sakaguchi, D. Habu, S. Shiomi, Y. Imanishi, N. Kawada, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus, Journal of Viral Hepatitis, 2010, 17, 2
  46. 46
    Erik De Clercq, Geoffrey Férir, Suzanne Kaptein, Johan Neyts, Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections, Viruses, 2010, 2, 6, 1279

    CrossRef

  47. 47
    Han Jak Ryu, Jung Min Lee, Sang Hoon Ahn, Do Young Kim, Myoung Ha Lee, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park, Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B, Journal of Medical Virology, 2010, 82, 11
  48. 48
    Pawinee Wongprasit, Weerawat Manosuthi, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph, Hepatitis B Virus Drug Resistance in HIV-1–Infected Patients Taking Lamivudine-Containing Antiretroviral Therapy, AIDS Patient Care and STDs, 2010, 24, 4, 205

    CrossRef

  49. 49
    Patrick Marcellin, Jean-François Cadranel, Thierry Fontanges, Thierry Poynard, Stanislas Pol, Christian Trepo, Patrick Blin, Bruno Bregman, Nathalie Schmidely, Françoise Roudot-Thoraval, Jean-Pierre Zarski, High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France, European Journal of Gastroenterology & Hepatology, 2010, 22, 11, 1290

    CrossRef

  50. 50
    Mashu Aizawa, Akihito Tsubota, Kiyotaka Fujise, Tetsuro Kato, Mitsuo Sakamoto, Toshifumi Ohkusa, Hisao Tajiri, Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype Ae infection with coinfection of human immunodeficiency virus, Hepatology Research, 2010, 40, 2
  51. 51
    Theodora E.M.S. de Vries–Sluijs, Jurriën G.P. Reijnders, Bettina E. Hansen, Hans L. Zaaijer, Jan M. Prins, Suzan D. Pas, Martin Schutten, Andy I.M. Hoepelman, Clemens Richter, Jan W. Mulder, Rob A. de Man, Harry L.A. Janssen, Marchina E. van der Ende, Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus, Gastroenterology, 2010, 139, 6, 1934

    CrossRef

  52. 52
    Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P. Reinders, Bernd Möller, Peter Rhode, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues, Hepatology, 2010, 51, 1
  53. 53
    Hui-Hui Tan, Paul Martin, Management of End-Stage Liver Disease in Chronic Hepatitis B, Clinics in Liver Disease, 2010, 14, 3, 477

    CrossRef

  54. 54
    T. Asselah, O. Lada, P. Marcellin, Résultats des essais thérapeutiques dans l’hépatite chronique B, Antibiotiques, 2010, 12, 1, 42

    CrossRef

  55. 55
    Alice M Jenh, Paul A Pham, Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 10, 1079

    CrossRef

  56. 56
    Thomas Berg, Patrick Marcellin, Fabien Zoulim, Bernd Moller, Huy Trinh, Sing Chan, Emilio Suarez, Fabien Lavocat, Andrea Snow–Lampart, David Frederick, Jeff Sorbel, Katyna Borroto–Esoda, David Oldach, Franck Rousseau, Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection, Gastroenterology, 2010, 139, 4, 1207

    CrossRef

  57. 57
    In Hee Kim, Seok Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Chang Soo Choi, Haak Cheoul Kim, Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B, Journal of Korean Medical Science, 2010, 25, 5, 738

    CrossRef

  58. 58
    Young Kul Jung, Jong Eun Yeon, Woo Sik Han, Ji Hoon Kim, Jeong Han Kim, Jong-Jae Park, Jae Seon Kim, Young-Tae Bak, Wangdon Yoo, Sun Pyo Hong, Soo-Ok Kim, So Young Kwon, Kwan Soo Byun, Chang Hong Lee, Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B, Gut and Liver, 2010, 4, 2, 212

    CrossRef

  59. 59
    Richard J. Whitley, Antibiotic and Chemotherapy, 2010,

    CrossRef

  60. 60
    MARGARET JAMES KOZIEL, CHLOE LYNNE THIO, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  61. 61
    Hyun Joo Suh, Moon Kyung Park, Hyang Ie Lee, Geum Yeon Gwak, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee, Antiviral Efficacy of Lamivudine/Adefovir Combination Therapy in Chronic Hepatitis B Patients with Resistance to Lamivudine and Adefovir Consecutively, The Korean Journal of Gastroenterology, 2009, 53, 5, 305

    CrossRef

  62. 62
    Marc G. Ghany, Edward C. Doo, Antiviral resistance and hepatitis B therapy, Hepatology, 2009, 49, S5
  63. 63
    Jules L. Dienstag, Benefits and risks of nucleoside analog therapy for hepatitis B, Hepatology, 2009, 49, S5
  64. 64
    Coralie Pallier, Christophe Rodriguez, Rozenn Brillet, Patrice Nordmann, Christophe Hézode, Jean-Michel Pawlotsky, Complex dynamics of hepatitis B virus resistance to adefovir, Hepatology, 2009, 49, 1
  65. 65
    Iñigo Les, Rita García-Martínez, Juan Córdoba, Manuel Quintana, Rafael Esteban, María Buti, Current trends in chronic hepatitis B management: results of a questionnaire, European Journal of Gastroenterology & Hepatology, 2009, 21, 10, 1177

    CrossRef

  66. 66
    Sammy Saab, Maggie Y. Ham, Michael A. Stone, Curtis Holt, Myron Tong, Decision analysis model for hepatitis B prophylaxis one year after liver transplantation, Liver Transplantation, 2009, 15, 4
  67. 67
    Jurriën G.P. Reijnders, Suzan D. Pas, Martin Schutten, Robert A. de Man, Harry L.A. Janssen, Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy, Journal of Hepatology, 2009, 50, 4, 674

    CrossRef

  68. 68
    Dennis J. Cada, Terri L. Levien, Danial E. Baker, Formulary Drug Reviews - Tenofovir Disoproxil Fumarate Tablets, Hospital Pharmacy, 2009, 44, 2, 165

    CrossRef

  69. 69
    Susanne Abbrederis, Wolfgang Vogel, Hepatitis B, Wiener klinische Wochenschrift Education, 2009, 4, 1, 43

    CrossRef

  70. 70
    Susanne Beckebaum, Georgios C. Sotiropoulos, Guido Gerken, Vito R. Cicinnati, Hepatitis B and liver transplantation: 2008 update, Reviews in Medical Virology, 2009, 19, 1
  71. 71
    Christian Markus Lange, Bernd Kronenberger, Stefan Zeuzem, Hepatitis B: Management of suboptimal response to oral antiviral therapy, Current Hepatitis Reports, 2009, 8, 4, 173

    CrossRef

  72. 72
    Helena N. Deeney, Geoff M. Dusheiko, Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change?, Transplant International, 2009, 22, 4
  73. 73
    Nao Kurashige, Kazuyoshi Ohkawa, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Tsugiko Oze, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Yoshinori Doi, Akira Yamada, Kazuto Fukuda, Masahide Oshita, Eiji Mita, Hiroyuki Fukui, Toshihiko Nagase, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Takeshi Kashihara, Norio Hayashi, Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance, Journal of Gastroenterology, 2009, 44, 8, 864

    CrossRef

  74. 74
    Jean-Pierre Zarski, Les nouvelles molécules dans la prise en charge de l’hépatite chronique virale B, La Presse Médicale, 2009, 38, 5, 692

    CrossRef

  75. 75
    Uzma Shah, Deirdre Kelly, Mei-Hwei Chang, Tomoo Fujisawa, Solange Heller, Regino P González-Peralta, Paloma Jara, Giorgina Mieli-Vergani, Neelam Mohan, Karen F Murray, Management of Chronic Hepatitis B in Children, Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 4, 399

    CrossRef

  76. 76
    Maria Buti, Max Brosa, Miguel A. Casado, Magdalena Rueda, Rafael Esteban, Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B, Journal of Hepatology, 2009, 51, 4, 640

    CrossRef

  77. 77
    Si Nafa Si Ahmed, Fabien Zoulim, Pathobiology of HBV mutants and clinical impact for treatment monitoring, Expert Review of Anti-infective Therapy, 2009, 7, 3, 309

    CrossRef

  78. 78
    Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai, Prevention and management of drug resistance for antihepatitis B treatment, The Lancet Infectious Diseases, 2009, 9, 4, 256

    CrossRef

  79. 79
    John D. Scott, Brian McMahon, Role of combination therapy in chronic hepatitis B, Current Gastroenterology Reports, 2009, 11, 1, 28

    CrossRef

  80. 80
    Janet C. Yang, Steven-Huy B. Han, Society guidelines, US treatment algorithm, and NIH consensus: Similarities and differences in management of hepatitis B, Current Hepatitis Reports, 2009, 8, 4, 161

    CrossRef

  81. 81
    Alice M. Jenh, Chloe L. Thio, Paul A. Pham, Tenofovir for the Treatment of Hepatitis B Virus, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009, 29, 10
  82. 82
    Samad Amini-Bavil-Olyaee, Ulf Herbers, Julie Sheldon, Tom Luedde, Christian Trautwein, Frank Tacke, The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen–positive and hepatitis B e antigen–negative hepatitis B virus strains, Hepatology, 2009, 49, 4
  83. 83
    David E. Brumbaugh, Ronald J. Sokol, Treatment of chronic hepatitis B virus infection in children, Current Hepatitis Reports, 2009, 8, 3, 96

    CrossRef

  84. 84
    Emmet B. Keeffe, Douglas T. Dieterich, Steven-Huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias, A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update, Clinical Gastroenterology and Hepatology, 2008, 6, 12, 1315

    CrossRef

  85. 85
    William Alazawi, Graham R Foster, Advances in the diagnosis and treatment of hepatitis B, Current Opinion in Infectious Diseases, 2008, 21, 5, 508

    CrossRef

  86. 86
    Gui-feng Wang, Li-ping Shi, Jian-ping Zuo, Anti-hepatitis B virus drugs in clinical and preclinical development, Virologica Sinica, 2008, 23, 2, 137

    CrossRef

  87. 87
    Geoffrey Férir, Suzanne Kaptein, Johan Neyts, Erik De Clercq, Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future, Reviews in Medical Virology, 2008, 18, 1
  88. 88
    C. Fournier, F. Zoulim, Associations thérapeutiques dans la prise en charge des hépatites chroniques B, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S42

    CrossRef

  89. 89
    Tin Nguyen, Stephen Locarnini, Paul Desmond, Changing landscape of antiviral resistance management in chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2008, 23, 9
  90. 90
    Ching-Lung Lai, Man-Fung Yuen, Chronic Hepatitis B — New Goals, New Treatment, New England Journal of Medicine, 2008, 359, 23, 2488

    CrossRef

  91. 91
    Emmet B. Keeffe, Douglas T. Dieterich, Jean–Michel Pawlotsky, Yves Benhamou, Chronic Hepatitis B: Preventing, Detecting, and Managing Viral Resistance, Clinical Gastroenterology and Hepatology, 2008, 6, 3, 268

    CrossRef

  92. 92
    Jennifer J Kiser, Christina L Aquilante, Peter L Anderson, Tracy M King, Monica L Carten, Courtney V Fletcher, Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2008, 47, 3, 298

    CrossRef

  93. 93
    Mari Inada, Osamu Yokosuka, Current antiviral therapies for chronic hepatitis B, Hepatology Research, 2008, 38, 6
  94. 94
    Ting-Tsung Chang, Dong Jin Suh, Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop, Hepatology International, 2008, 2, S1, 19

    CrossRef

  95. 95
    Fabien Zoulim, Données actuelles sur le traitement de l’hépatite B chronique, La Presse Médicale, 2008, 37, 2, 287

    CrossRef

  96. 96
    Hyung Joon Kim, Entecavir 1 mg therapy for lamivudine-refractory chronic hepatitis B, The Korean Journal of Hepatology, 2008, 14, 3, 411

    CrossRef

  97. 97
    Morris Sherman, Cihan Yurdaydin, Halis Simsek, Marcelo Silva, Yun-Fan Liaw, Vinod K. Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, James Vaughan, Bruce Kreter, Robert Hindes, Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks, Hepatology, 2008, 48, 1
  98. 98
    Ellen Kitchell, Mamta K. Jain, Evaluation and treatment of the patient coinfected with hepatitis B and HIV, Current HIV/AIDS Reports, 2008, 5, 3, 103

    CrossRef

  99. 99
    A. Gallego, J. Sheldon, J. García-Samaniego, N. Margall, M. Romero, P. Hornillos, V. Soriano, J. Enríquez, Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B, Journal of Viral Hepatitis, 2008, no

    CrossRef

  100. 100
    A. Gallego, J. Sheldon, J. García-Samaniego, N. Margall, M. Romero, P. Hornillos, V. Soriano, J. Enríquez, Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B, Journal of Viral Hepatitis, 2008, 15, 5
  101. 101
    M. Viganò, P. Lampertico, F. Facchetti, G. Lunghi, M. Colombo, Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine, Journal of Viral Hepatitis, 2008, 15, 12
  102. 102
    Fabien Zoulim, Robert Perrillo, Hepatitis B: Reflections on the current approach to antiviral therapy, Journal of Hepatology, 2008, 48, S2

    CrossRef

  103. 103
    Anna S. F. Lok, How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting, Liver Transplantation, 2008, 14, S2
  104. 104
    J.-P. Zarski, V. Leroy, Le patient atteint d’hépatite chronique B non contrôlé, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S7

    CrossRef

  105. 105
    Peter W. Angus, Scott J. Patterson, Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin/antiviral regimen?, Liver Transplantation, 2008, 14, S2
  106. 106
    Hiromi Yatsuji, Fumitaka Suzuki, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Sachiyo Watahiki, Satomi Iwasaki, Mariko Kobayashi, Hiromitsu Kumada, Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up, Journal of Hepatology, 2008, 48, 6, 923

    CrossRef

  107. 107
    Fabien Zoulim, Sylvie Radenne, Christian Ducerf, Management of patients with decompensated hepatitis B virus associated cirrhosis, Liver Transplantation, 2008, 14, S2
  108. 108
    Mei-Hwei Chang, Natural history and clinical management of chronic hepatitis B virus infection in children, Hepatology International, 2008, 2, S1, 28

    CrossRef

  109. 109
    Bart Takkenberg, Joep de Bruijne, Christine Weegink, Peter Jansen, Hendrik Reesink, Novel therapies in hepatitis B and C, Current Gastroenterology Reports, 2008, 10, 1, 81

    CrossRef

  110. 110
    Rong-Nan Chien, Yun-Fan Liaw, Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1081

    CrossRef

  111. 111
    Curtis L. Cooper, Obstacles to Successful HCV Treatment in Substance Addicted Patients, Journal of Addictive Diseases, 2008, 27, 2, 61

    CrossRef

  112. 112
    J.G.P. Reijnders, H.L.A. Janssen, Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?, Journal of Hepatology, 2008, 48, 3, 383

    CrossRef

  113. 113
    F. Poordad, K. R. Reddy, P. Martin, Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C, Clinical Infectious Diseases, 2008, 46, 1, 78

    CrossRef

  114. 114
    Nancy Leung, Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues, Hepatology International, 2008, 2, 2, 163

    CrossRef

  115. 115
    George V Papatheodoridis, Melanie Deutsch, Resistance issues in treating chronic hepatitis B, Future Microbiology, 2008, 3, 5, 525

    CrossRef

  116. 116
    Paul Martin, Donald M Jensen, Ribavirin in the treatment of chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 6
  117. 117
    Florian van Bömmel, Thomas Berg, Role of tenofovir in the treatment of chronic HBV infection, Future Virology, 2008, 3, 3, 207

    CrossRef

  118. 118
    Hie-Won Hann, Hee Bok Chae, Stephen R. Dunn, Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV), Hepatology International, 2008, 2, 2, 244

    CrossRef

  119. 119
    Patrick Marcellin, E. Jenny Heathcote, Maria Buti, Ed Gane, Robert A. de Man, Zahary Krastev, George Germanidis, Sam S. Lee, Robert Flisiak, Kelly Kaita, Michael Manns, Iskren Kotzev, Konstantin Tchernev, Peter Buggisch, Frank Weilert, Oya Ovung Kurdas, Mitchell L. Shiffman, Huy Trinh, Mary Kay Washington, Jeff Sorbel, Jane Anderson, Andrea Snow-Lampart, Elsa Mondou, Joe Quinn, Franck Rousseau, Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, 2008, 359, 23, 2442

    CrossRef

  120. 120
    Jessica Tan, Bulent Degertekin, Stephen N. Wong, Munira Husain, Kelly Oberhelman, Anna S.F. Lok, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations, Journal of Hepatology, 2008, 48, 3, 391

    CrossRef

  121. 121
    Won Hyeok Choe, So Young Kwon, Byung Kook Kim, Soon Young Ko, Jong Eun Yeon, Kwan Soo Byun, Gyun-Hwan Kim, Chang Hong Lee, Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis, Liver International, 2008, 28, 6
  122. 122
    S. Gutierrez, S. Guillemi, N. Jahnke, V. Montessori, P. R. Harrigan, J. S. G. Montaner, Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine, Clinical Infectious Diseases, 2008, 46, 3, e28

    CrossRef

  123. 123
    JJ Kiser, ML Carten, CL Aquilante, PL Anderson, P Wolfe, TM King, T Delahunty, LR Bushman, CV Fletcher, The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients, Clinical Pharmacology & Therapeutics, 2008, 83, 2
  124. 124
    George V Papatheodoridis, Spilios Manolakopoulos, Geoffrey Dusheiko, Athanasios J Archimandritis, Therapeutic strategies in the management of patients with chronic hepatitis B virus infection, The Lancet Infectious Diseases, 2008, 8, 3, 167

    CrossRef

  125. 125
    F. Bailly, F. Zoulim, Traitement de l’hépatite B. Conduite thérapeutique, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S172

    CrossRef

  126. 126
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  127. 127
    M. Bourlière, P. Castellani, Traitement de l’hépatite chronique B : nouvelles perspectives, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S64

    CrossRef

  128. 128
    Bijal Surti, Amanda C. Chi, Sammy Saab, Update on management of hepatitis B before and after liver transplantation, Current Hepatitis Reports, 2008, 7, 1, 25

    CrossRef

  129. 129
    Jessica Tan, Anna S.F. Lok, Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B, Liver Transplantation, 2007, 13, 3
  130. 130
    Claire Fournier, Fabien Zoulim, Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance, Clinics in Liver Disease, 2007, 11, 4, 869

    CrossRef

  131. 131
    Oliver Schildgen, Florian van Bömmel, Jürgen K Rockstroh, Current and future therapies for chronic HBV-infections, Reviews in Medical Microbiology, 2007, 18, 4, 79

    CrossRef

  132. 132
    Margarita Pardo, Javier Bartolomé, Vicente Carreño, Current Therapy of Chronic Hepatitis B, Archives of Medical Research, 2007, 38, 6, 661

    CrossRef

  133. 133
    Marc Ghany, T. Jake Liang, Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B, Gastroenterology, 2007, 132, 4, 1574

    CrossRef

  134. 134
    H. L.-Y. CHAN, V. W.-S. WONG, C.-H. TSE, A. M.-L. CHIM, H.-Y. CHAN, G. L.-H. WONG, J. J.-Y. SUNG, Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 25, 8
  135. 135
    Christophe Hézode, Stéphane Chevaliez, Magali Bouvier-Alias, Françoise Roudot-Thoraval, Rozenn Brillet, Elie-Serge Zafrani, Daniel Dhumeaux, Jean-Michel Pawlotsky, Efficacy and safety of adefovir dipivoxil 20mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10mg daily, Journal of Hepatology, 2007, 46, 5, 791

    CrossRef

  136. 136
    Nobuyuki Takemura, Yasuhiko Sugawara, Sumihito Tamura, Masatoshi Makuuchi, Liver Transplantation Using Hepatitis B Core Antibody−Positive Grafts: Review and University of Tokyo Experience, Digestive Diseases and Sciences, 2007, 52, 10, 2472

    CrossRef

  137. 137
    Pietro Lampertico, Mauro Viganò, Elena Manenti, Massimo Iavarone, Erwin Sablon, Massimo Colombo, Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients, Gastroenterology, 2007, 133, 5, 1445

    CrossRef

  138. 138
    Kwan Sik Lee, Dong Joon Kim, Management of Chronic Hepatitis B, The Korean Journal of Hepatology, 2007, 13, 4, 447

    CrossRef

  139. 139
    Carla S. Coffin, Norah A. Terrault, Management of hepatitis B in liver transplant recipients, Journal of Viral Hepatitis, 2007, 14,
  140. 140
    Jay H. Hoofnagle, Edward Doo, T. Jake Liang, Russell Fleischer, Anna S.F. Lok, Management of hepatitis B: Summary of a clinical research workshop, Hepatology, 2007, 45, 4
  141. 141
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  142. 142
    María Buti, Francisco Rodríguez Frías, José Luis Calleja, Rosendo Jardí, Fernando Pons, Javier Crespo, Teresa Casanovas, Jaime Enríquez, Fernando Carnicer, Manuel Romero, Manuel García Bengoechea, Martín Prieto, Javier García Samaniego, Manuel Miras, Francisco Pérez Roldán, Magdalena Rueda, Rafael Esteban, Programa de uso compasivo con adefovir dipivoxil en España: valoración de su eficacia y estudio de las resistencias, Medicina Clínica, 2007, 129, 15, 566

    CrossRef

  143. 143
    Britta Ranneberg, Thomas Mertenskoetter, Gill Pearce, Response to Blaas et al., ‘Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases’, AIDS, 2007, 21, 6, 783

    CrossRef

  144. 144
    Maurizia Rossana Brunetto, Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance, Journal of Hepatology, 2007, 46, 5, 756

    CrossRef

  145. 145
    David J Quan, Marion G Peters, Tenofovir disoproxil fumarate for the treatment of hepatitis B virus infection: pharmacokinetics and clinical efficacy, Therapy, 2007, 4, 2, 141

    CrossRef

  146. 146
    Gail Matthews, The management of HIV and hepatitis B coinfection, Current Opinion in Infectious Diseases, 2007, 20, 1, 16

    CrossRef

  147. 147
    Jessica Tan, Anna SF Lok, Update on viral hepatitis: 2006, Current Opinion in Gastroenterology, 2007, 23, 3, 263

    CrossRef

  148. 148
    Erik De Clercq, 2007,

    CrossRef

  149. 149
    HIV drug shows promise in HBV treatment, Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3, 11, 603

    CrossRef

  150. 150
    Oliver Schildgen, Martin Helm, Wolfram Gerlich, Nonresponse to adefovir: Host or virus dependent?, Journal of Clinical Virology, 2006, 37, 4, 327

    CrossRef

  151. 151
    Marion G. Peters, Janet Andersen, Patrick Lynch, Tun Liu, Beverly Alston-Smith, Carol L. Brosgart, Jeffrey M. Jacobson, Victoria A. Johnson, Richard B. Pollard, James F. Rooney, Kenneth E. Sherman, Susan Swindells, Bruce Polsky, Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127, Hepatology, 2006, 44, 5
  152. 152
    Stephen N. Wong, Anna S.F. Lok, Tenofovir disoproxil fumarate: Role in hepatitis B treatment, Hepatology, 2006, 44, 2
  153. 153
    Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì, Hepatitis B: Prognosis and Treatment,
  154. 154
    Veerendra Sandur, George Therapondos, Infections in the Liver,